Capital Analysts, LLC Biogen Inc. Transaction History

Capital Analysts, LLC

$2.26 Billion
Q2 2024

A detailed history of Capital Analysts, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Capital Analysts, LLC holds 516 shares of BIIB stock, worth $89,536. This represents 0.01% of its overall portfolio holdings.

Number of Shares

516

Previous 516 -0.0%

Holding current value

$89,536

Previous $111,000 8.11%

% of portfolio

0.01%

Previous 0.01%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 05, 2023	SELL	$256.56 - $292.34 $73,119 - $83,316	-285 Reduced 35.58%	516 $143,000
Q1 2021 May 17, 2021	BUY	$242.95 - $284.63 $69,240 - $81,119	285 Added 55.23%	801 $224,000
Q2 2020 Aug 07, 2020	SELL	$258.66 - $342.55 $31,039 - $41,106	-120 Reduced 18.87%	516 $138,000
Q1 2020 May 08, 2020	SELL	$268.85 - $341.04 $66,137 - $83,895	-246 Reduced 27.89%	636 $201,000
Q4 2019 Feb 12, 2020	BUY	$220.06 - $304.07 $22,666 - $31,319	103 Added 13.22%	882 $262,000
Q3 2019 Nov 12, 2019	SELL	$217.44 - $243.88 $10,002 - $11,218	-46 Reduced 5.58%	779 $181,000
Q2 2019 Aug 13, 2019	SELL	$219.29 - $241.72 $21,051 - $23,205	-96 Reduced 10.42%	825 $193,000
Q1 2019 May 13, 2019	BUY	$216.71 - $338.96 $51,360 - $80,333	237 Added 34.65%	921 $217,000
Q4 2018 Feb 13, 2019	BUY	$278.5 - $352.75 $33,141 - $41,977	119 Added 21.06%	684 $206,000
Q3 2018 Nov 07, 2018	BUY	$293.51 - $383.83 $21,132 - $27,635	72 Added 14.6%	565 $0
Q1 2018 May 14, 2018	BUY	$260.13 - $367.91 $27,573 - $38,998	106 Added 27.39%	493 $135,000
Q4 2017 Feb 14, 2018	SELL	$307.64 - $344.58 $14.6 Million - $16.4 Million	-47,471 Reduced 99.19%	387 $123,000
Q4 2017 Feb 12, 2018	BUY	$307.64 - $344.58 $14.6 Million - $16.4 Million	47,471 Added 12266.41%	47,858 $2.56 Million
Q3 2017 Nov 06, 2017	BUY	$281.15 - $329.69 $108,805 - $127,590	387	387 $121,000

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Analysts, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Analysts, LLC with notifications on news.

Account

Capital Analysts, LLC Biogen Inc. Transaction History